Tarsus Pharmaceuticals (TARS) Competitors $51.74 +1.09 (+2.15%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$51.74 -0.01 (-0.01%) As of 03/28/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. ROIV, SRPT, RVMD, BBIO, LNTH, TGTX, LEGN, AXSM, TLX, and BPMCShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Roivant Sciences (ROIV), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Lantheus (LNTH), TG Therapeutics (TGTX), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Roivant Sciences Sarepta Therapeutics Revolution Medicines BridgeBio Pharma Lantheus TG Therapeutics Legend Biotech Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Roivant Sciences (NASDAQ:ROIV) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Which has better valuation and earnings, ROIV or TARS? Roivant Sciences has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$122.59M60.42$4.35B-$0.15-69.20Tarsus Pharmaceuticals$182.95M10.85-$135.89M-$3.10-16.69 Does the media refer more to ROIV or TARS? In the previous week, Roivant Sciences had 7 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 13 mentions for Roivant Sciences and 6 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.32 beat Roivant Sciences' score of 0.92 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ROIV or TARS more profitable? Tarsus Pharmaceuticals has a net margin of -103.64% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Tarsus Pharmaceuticals -103.64%-55.86%-39.28% Do analysts recommend ROIV or TARS? Roivant Sciences presently has a consensus price target of $17.10, suggesting a potential upside of 64.74%. Tarsus Pharmaceuticals has a consensus price target of $63.67, suggesting a potential upside of 23.05%. Given Roivant Sciences' higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ROIV or TARS? Roivant Sciences received 2 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 78.26% of users gave Roivant Sciences an outperform vote while only 68.42% of users gave Tarsus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% Tarsus PharmaceuticalsOutperform Votes5268.42% Underperform Votes2431.58% Do insiders & institutionals have more ownership in ROIV or TARS? 64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ROIV or TARS? Roivant Sciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. SummaryRoivant Sciences beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Remove Ads Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.99B$3.03B$5.63B$7.83BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-13.5828.9323.3318.67Price / Sales10.85429.70388.3491.01Price / CashN/A168.6838.1634.64Price / Book8.703.926.894.23Net Income-$135.89M-$71.95M$3.20B$247.15M7 Day Performance3.54%-5.55%-2.98%-2.17%1 Month Performance16.32%-11.96%1.63%-5.68%1 Year Performance42.34%-27.81%9.44%-0.74% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals2.0972 of 5 stars$51.74+2.2%$63.67+23.1%+42.3%$1.99B$182.95M-13.5850Insider TradePositive NewsROIVRoivant Sciences2.359 of 5 stars$10.83+0.4%$18.08+67.0%-1.5%$7.73B$122.59M-72.20860SRPTSarepta Therapeutics4.8256 of 5 stars$76.33+3.0%$167.41+119.3%-45.6%$7.41B$1.90B61.061,314RVMDRevolution Medicines4.1315 of 5 stars$39.34+3.2%$66.31+68.6%+15.9%$7.31B$742,000.00-10.96250Positive NewsBBIOBridgeBio Pharma4.5948 of 5 stars$37.22+7.0%$52.90+42.1%+13.6%$7.08B$221.90M-13.06400Insider TradeHigh Trading VolumeLNTHLantheus4.2597 of 5 stars$99.44+1.8%$129.43+30.2%+54.5%$6.81B$1.53B16.55700TGTXTG Therapeutics3.0428 of 5 stars$42.61-0.9%$40.67-4.6%+162.1%$6.69B$329.00M-426.06290Positive NewsLEGNLegend Biotech2.8557 of 5 stars$36.33-1.7%$79.00+117.5%-37.5%$6.67B$627.24M-38.241,800Short Interest ↓Positive NewsAXSMAxsome Therapeutics4.7455 of 5 stars$129.17+1.9%$167.36+29.6%+48.5%$6.30B$385.69M-21.56380Analyst ForecastShort Interest ↓TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.24+2.5%$22.00+20.6%N/A$6.14B$783.21M0.00N/AGap UpBPMCBlueprint Medicines2.7806 of 5 stars$95.27+7.4%$124.95+31.2%-6.5%$6.09B$508.82M-88.21640Insider TradePositive News Remove Ads Related Companies and Tools Related Companies Roivant Sciences Alternatives Sarepta Therapeutics Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Lantheus Alternatives TG Therapeutics Alternatives Legend Biotech Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARS Stock Free TARS Stock Alerts